Back to top
more

Galena Biopharma, Inc. (GALE)

(Real Time Quote from BATS)

$0.26 USD

0.26
NA

-0.01 (-5.11%)

Updated Dec 29, 2017 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4

Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

    AbbVie and J&J Present Positive Imbruvica Leukemia Data

    AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).

      Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

      Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.

        Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

        Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

          Valeant (VRX) Q1 Earnings & Revenues Miss, View Raised

          Shares of Valeant Pharmaceuticals Inc. (VRX) surged significantly after the company raised the annual guidance for 2017 concurrent with the first-quarter 2017 earnings.

            Prothena (PRTA) Q1 Loss Narrower than Expected, Updates View

            Prothena Corporation plc (PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents.

              Infinity (INFI) Reports Narrower-than-Expected Loss in Q1

              Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.

                Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

                Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.

                  Endo (ENDP) Beats on Q1 Earnings, Reaffirms '17 Guidance

                  Endo International plc's (ENDP) first-quarter 2017 earnings from continuing operations was $1.23 per share which topped the Zacks Consensus Estimate of $1.12. Earnings were also above the year-ago figure of $1.08.

                    Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed

                    Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.

                      Mallinckrodt Earnings, Revenues Beat Estimates in Q1

                      Mallinckrodt Public Limited Company (MNK) reported first-quarter 2017 results wherein both sales and earnings beat expectations.

                        ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1

                        ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.

                          Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1

                          Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents.

                            Juno Therapeutics (JUNO) Posts Wider-than-Expected Q1 Loss

                            Juno Therapeutics Inc. (JUNO) reported first-quarter 2017 loss of 71 cents per share (including stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 66 cents.

                              Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus

                              Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.

                                Zoetis (ZTS) Beats Earnings, Revenue Estimates in Q1

                                Zoetis Inc. (ZTS) first-quarter 2017 earnings of 53 cents per share increased 10% year over year and surpassed the Zacks Consensus Estimate of 48 cents.

                                  Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

                                  Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

                                    AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates

                                    AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.

                                      Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss

                                      Acorda Therapeutics, Inc. (ACOR) reported loss of 25 cents per share in the first quarter of 2017 (including the impact of stock-based compensation expenses), wider than the Zacks Consensus Estimate of a loss of 16 cents.

                                        Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

                                        Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.

                                          AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y

                                          AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.

                                            Bayer (BAYRY) Beats Q1 Earnings, Revenue Estimates

                                            Bayer AG's (BAYRY) first-quarter 2017 core earnings per share from continuing operations was $2.80 which beat the Zacks Consensus Estimate of $2.40.

                                              Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View

                                              Alexion Pharmaceuticals, Inc.'s (ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.

                                                CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

                                                CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).

                                                  Bet on Rising P/E with These 5 Top-Ranked Stocks

                                                  Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.